Special Issues
Table of Content

AI, Radiomics, and Radiogenomics in Urologic Oncology: Toward a New Era of Precision Imaging

Submission Deadline: 30 June 2026 View: 586 Submit to Special Issue

Guest Editor(s)

Dr. Federico Greco

Email: federico.greco@unicampus.it

Affiliation: Department of Radiology, Cittadella della Salute, Azienda Sanitaria Locale di Lecce, Piazza Filippo Bottazzi, 2, 73100 Lecce, Italy.

Research Unit of Radiology, Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Via Alvaro del Portillo, 21, 00128 Roma, Italy.

Homepage:

Research Interests: artificial intelligence, body composition, radiogenomics, urologic oncology

图片1.png


Prof. Dr. Carlo Augusto Mallio

Email: c.mallio@policlinicocampus.it

Affiliation: Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo, 200, 00128 Roma, Italy.

Research Unit of Radiology, Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Via Alvaro del Portillo, 21, 00128 Roma, Italy.

Homepage:

Research Interests: artificial intelligence, body composition, radiogenomics, urologic oncology

图片2.png


Summary

The rapid integration of artificial intelligence (AI), radiogenomics, and radiomics into clinical research is transforming the landscape of urologic oncology. These technologies enable a deeper understanding of tumor biology, non-invasive characterization of disease, and personalized treatment planning, offering unprecedented opportunities to improve patient outcomes. In particular, radiogenomics—linking imaging features with genomic profiles—has emerged as a powerful approach to bridge diagnostic imaging with molecular data.


This Special Issue aims to explore the intersection of AI, radiomics, and radiogenomics in the diagnosis, prognosis, and treatment of urologic cancers, including prostate, bladder, and kidney malignancies. The goal is to gather innovative research and expert reviews that demonstrate how these tools can enhance clinical decision-making and pave the way toward precision oncology in urology.


Suggested themes include:
1)  Artificial intelligence for imaging-based risk stratification in urologic oncology
2)  Radiomics applications in assessing tumor heterogeneity and treatment response
3)  Radiogenomic approaches linking imaging phenotypes with molecular markers
4)  Body composition analysis (e.g., adipose tissue compartments quantification) using AI and its prognostic value in urologic cancers
5)  Integration of radiogenomic data into predictive models for personalized therapy
6)  Advances in machine learning techniques for multi-parametric imaging interpretation
7)  Challenges and opportunities in clinical translation of AI-based radiomic and radiogenomic tools

This Special Issue welcomes original research, comprehensive reviews, and translational studies that contribute to advancing the field of AI-assisted urologic oncology.


Keywords

artificial intelligence, body composition, radiogenomics, radiomics, urologic oncology

Published Papers


  • Open Access

    REVIEW

    The role of artificial intelligence in urological malignancies: an overview of systematic reviews

    Vasileios Sakalis, Eftichia Chatzigriva, Karl H. Pang, Bhavan P. Rai, Isaak Filippidis, Lisa Moris, Maria Chalkidou, Yuhong Yuan, Michael Bussmann, Dimitrios Papanikolaou, James N’Dow, Muhammad Imran Omar
    Canadian Journal of Urology, DOI:10.32604/cju.2026.077632
    (This article belongs to the Special Issue: AI, Radiomics, and Radiogenomics in Urologic Oncology: Toward a New Era of Precision Imaging)
    Abstract Objectives: Artificial Intelligence (AI) has the potential to transform clinical medicine by enhancing diagnostic precision, prognostic accuracy, and personalized decision making. In urological oncology, AI technologies are increasingly integrated across diagnostic, prognostic, and therapeutic pathways. This overview of systematic reviews aims to synthesise the current evidence on the performance and clinical utility of AI applications in urological malignancies. Methods: A systematic search was conducted of major bibliographic databases from 1974 to October 2024 to identify systematic reviews (SRs) evaluating AI-based models in urological cancers. We followed the Cochrane methodology of Overviews of Reviews. Outcomes of… More >

  • Open Access

    ARTICLE

    AI-driven radiogenomic analysis of clear cell renal cell carcinoma: perinephric adipose tissue stranding as a key feature of the NIPAL4-associated imaging pattern

    Federico Greco, Marco Cataldo, Valerio D’Andrea, Luca Pugliese, Andrea Panunzio, Alessandro Tafuri, Bruno Beomonte Zobel, Carlo Augusto Mallio
    Canadian Journal of Urology, Vol.32, No.5, pp. 433-443, 2025, DOI:10.32604/cju.2025.068390
    (This article belongs to the Special Issue: AI, Radiomics, and Radiogenomics in Urologic Oncology: Toward a New Era of Precision Imaging)
    Abstract Background: Radiogenomics offers a non-invasive approach to correlate imaging features with tumor molecular profiles. This study aims to identify computed tomography (CT) imaging characteristics associated with positive NIPA-like domain containing 4 (NIPAL4) expression in clear cell renal cell carcinoma (ccRCC) and to develop a radiogenomic predictive model to support personalized risk stratification. Methods: A retrospective analysis was conducted on 241 ccRCC patients from The Cancer Genome Atlas (TCGA) and The Cancer Imaging Archive (TCIA) databases. Clinical, pathological, and CT features were compared between NIPAL4-positive and NIPAL4-negative groups. A penalized logistic regression model was built to… More >

Share Link